Emily Mullin
banner
emilymullin.bsky.social
Emily Mullin
@emilymullin.bsky.social
Staff writer @wired.com, covering biotech (you know, the stuff that sounds like science fiction, but isn't)
Contact me: emullin.06 on Signal or emily_mullin@wired.com
emilymullin.com
It's been nearly two years since the first gene-editing therapy, Casgevy, was approved for sickle cell disease. Just 39 patients worldwide have received it in that time. This is from a Nov. 10 update from manufacturer Vertex:
November 12, 2025 at 4:58 PM
Over on the other site, gene-editing scientist Lucas Harrington announced a new company to explore "preventive gene editing."

In case you're counting, this is the third startup openly pursuing plans to edit human embryos. More on the company here: www.preventive.bio/blog/announc...
November 3, 2025 at 2:35 PM
Day 2 of ACIP: The committee just voted 11-1 in favor of tabling the hepatitis B vaccine issue. This was the anticipated vote language:
September 19, 2025 at 1:09 PM
The National Review, a leading conservative magazine, tells RFK Jr., "Don't abandon mRNA." www.nationalreview.com/2025/08/dont...
August 7, 2025 at 2:54 PM
The funny thing about this DEI reporting form that was sent to HHS employees yesterday is that literally anyone on the internet can fill it out: forms.office.com/pages/respon...
July 8, 2025 at 1:54 PM
Hmm, I thought AI was supposed to speed up the FDA's review process?
June 16, 2025 at 3:43 PM
Former CEO of 23andMe Anne Wojcicki won her company back late Friday with a $305 million offer made through a new nonprofit she established, TTAM Research Institute. Here's what Wojcicki is promising customers: investors.23andme.com/news-release...
June 16, 2025 at 1:39 PM
(2/3) It's not a new feat. Here's a participant from a 2012 study using a brain-computer interface (BCI) to control a robotic arm to drink from a bottle. See the pedestal and wire on her head? Not exactly ideal for everyday use.
November 26, 2024 at 2:58 PM